e-session 422 Highlights of ABC4 - ESO-ESMO Advanced Breast Cancer Fourth International Consensus Conference

Transcription

1 e-session 422 Highlights of ABC4 - ESO-ESMO Advanced Breast Cancer Fourth International Consensus Conference Expert: Dr Fatima Cardoso, Champalimaud Clinical Center Lisbon, Portugal Discussant: Prof Giuseppe Curigliano, European Institute of Oncology, Milan, Italy Extract from the e-eso policy The website contains presentations aimed at providing new knowledge and competences, and is intended as an informational and educational tool mainly designed for oncology professionals and other physicians interested in oncology. These materials remain property of the authors or ESO respectively. ESO is not responsible for any injury and/or damage to persons or property as a matter of a products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material published in these presentations. Because of the rapid advances in medical sciences, we recommend that independent verification of diagnoses and drugs dosages should be made. Furthermore, patients and the general public visiting the website should always seek professional medical advice. Finally, please note that ESO does not endorse any opinions expressed in the presentations. To share your e-eso experience use: #e_eso 2

2 Highlights from ABC 4 F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESO Breast Cancer Program Coordinator ESMO Board of Directors & NR Committee Chair EORTC Breast Group Past-Chair 2

3 DISCLOSURES Consultant/Ad Board: Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, GlaxoSmithKline, Macrogenics, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, Roche, Sanofi, Seattle Genetics, Teva 4

4 Fourth ESO-ESMO International Consensus Conference ABC4 was held under the High Patronage of and had the Opening made by His Excellency the President of the Portuguese Republic participants from 88 countries 4

5 ABC 4 Guidelines SCIENTIFIC ADVANCES What have we achieved in the last 2 years that is ready for implementation in clinical practice??? OTHER (perhaps even more important) ADVANCES 5

6 6 5 year survival rates for mbc still around 25% 5-year Survival Rates by Stage at Diagnosis (Female Breast Cancer, US SEER), Compared with ,2 WHY?? CAN WE IMPROVE? 1. American Cancer Society. Breast Cancer Facts & Figures Atlanta, GA: American Cancer Society; National Cancer Institute. SEER stat fact sheets: breast cancer. Accessed July 31,

7 STOP ACCEPTING PFS BENEFIT ALONE AS THE MAIN GOAL OS MUST BE AT LEAST A CO-PRIMARY COLLECT POST-PROGRESSION DATA THINK OF INNOVATIVE TRIAL DESIGNS USE OF REAL WORLD DATA 9

8 Characterize and understand exceptional responders 8

9 9 Analysis suggests limited improvement in quality of life for patients with mbc over the last decade EQ-5D Score Quality of life in patients with mbc as assessed by EQ-5D, , Generic (non-cancer Specific) Health Utility Score An analysis of the trends in quality of life for mbc* indicates that there has not been significant improvement over the past decade 2 In fact, there has been a slight decrease in quality of life *Analysis was based on a review of 132 articles, of which a quantitative analysis was conducted of 14 studies reporting QoL measure values for mbc. Values are weighted based on sample size. This analysis indicates a numerical decrease over time. It does not intend to demonstrate statistical significance 1. Here & Now, Novartis, Global Status of Advances/Metastatic Breast Cancer, Decade Report, March

10 10 Analysis suggests limited improvement in quality of life for patients with mbc over the last decade EQ-5D Score Quality of life in patients with mbc as assessed by EQ-5D, , Generic (non-cancer Specific) Health Utility Score An analysis of the trends in quality of life for mbc* indicates that there has not been significant improvement over the past decade 2 In fact, there has been a slight decrease in quality of life CAN WE DO BETTER? *Analysis was based on a review of 132 articles, of which a quantitative analysis was conducted of 14 studies reporting QoL measure values for mbc. Values are weighted based on sample size. This analysis indicates a numerical decrease over time. It does not intend to demonstrate statistical significance 1. Here & Now, Novartis, Global Status of Advances/Metastatic Breast Cancer, Decade Report, March

11 STOP PRESCRIBING SO MUCH UNECESSARY CT NOT ALL PATIENTS NEEDS COMBINATION OF ET + TARGETED NEED FOR CHANGE IN REIMBOURSEMENT RULES Current rules do not facilitate oral, less toxic treatments, nor shorter treatments of radiotherapy 13

12 DEVELOP BETTER AND SPECIFIC QoL TOOLS ASK EXPERTS FOR HELP WHEN CHOOSING QoL TOOLS AND ENDPOINTS Title Improving Health-Related Quality of Life in Metastatic Breast Cancer. Taking stock of achievements and delivering better measurement? Principal Investigator(s) & contact details Group Membership of Principal Investigator(s) Galina Velikova University of Leeds, UK and EORTC QLG Fatima Cardoso Champalimaud Clinical Center Lisbon, Portugal and chair of Breast Cancer Group EORTC Quality of Life Group Other EORTC group: Breast Cancer Group Ongoing project: Development of a QoL tool specific for ABC 14

13 Ongoing project: Development of Quality Indicators for ABC/MBC 13

14 Cancer World 2012, M. Beishon TREAT PATIENTS ACCORDING TO GUIDELINES IN A MULTIDISCIPLINARY, SPECIALIZED TEAM 16

15 TRAIN THE NEW GENERATION OF ONCOLOGISTS INCREASE ONCOLOGY WORKFORCE IN DEVELOPPING COUNTRIES 15

16 ACCESS TO CARE 18

17 We strongly recommend the use of objective scales, such as the ESMO Magnitude of Clinical Benefit Scale or the ASCO Value Framework, to evaluate the real magnitude of benefit provided by a new treatment and help prioritize funding, particularly in countries with limited resources. (LoE: Expert opinion) (88%) ESMO Magnitude of Clinical Benefit Scale 17

18 Meaningful benefit is lacking in the vast majority of EMA-approved cancer medications over the last 5 years: 89% (95% CI 80.0e95.7) and 79% (95% CI 68.6e87.1) of therapies do not meet the clinical benefit threshold in the adapted and original ESMO-MCBS, respectively. 18

19 cancer drug approvals based on surrogate outcomes have become more commonplace, lowering clinical trial costs, participant numbers, and follow-up times, but often still require postmarketing assessments of OS and QoL. And, although these studies are often delayed or fail to fulfil their obligations, the approval status remains firm. Thus, surrogate outcomes lead to faster medicine access, but poor correlations with clinical benefit. N. Grössmann et al. EJC , 66-71DOI: ( /j.ejca ) 19

20 Regarding the evidence for new cancer drugs, the bar has been dropping, which has been justified by the high benefit of new drugs. We showed, however, that the price of drugs was not related to their benefit to society and patients. 20

21 ABC 4 Guidelines ER POSITIVE/HER-2 NEGATIVE ABC 21

22 ER POSITIVE / HER-2 NEGATIVE MBC Many trials in ER+ ABC have not included pre-menopausal women. Despite this, we recommend that young women with ER+ ABC should have adequate ovarian suppression or ablation (OS/OA) and then be treated in the same way as post-menopausal women with endocrine agents with or without targeted therapies. (LoE/GoR: Expert Opinion/A) (95%) Future trials exploring new endocrine-based strategies should be designed to allow for enrollment of both pre- and post-menopausal women. (LoE/GoR: Expert Opinion/A) (92%) 22

23 ER POSITIVE / HER-2 NEGATIVE MBC The addition of everolimus to an AI is a valid option for some patients previously exposed to endocrine therapy, since it significantly prolongs PFS, albeit without OS benefit. The decision to treat must take into account the toxicities associated, with this combination, lack of statistical significant OS benefit, cost and availability. (LoE/GoR : I/B) (88%) Tamoxifen or Fulvestrant can also be combined with everolimus. (LoE/GoR : II/B) (80%) Adequate prevention, close monitoring and proactive treatment of adverse events is needed, particularly in older patients treated with everolimus due to the increased incidence of toxic deaths reported in the Bolero-2 trial. (LoE/GoR : I/B) (97%) 23 * For pre and peri with OS/OA, and post-menopausal women and men

24 ER POSITIVE / HER-2 NEGATIVE MBC The addition of a CDK4/6 inhibitor to an aromatase inhibitor, in patients naïve or pre-exposed to ET, provided a significant improvement in median PFS (~10 months), with an acceptable toxicity profile, and is therefore one of the preferred treatment options*. Patients relapsing < 12 months from the end of adjuvant AI were not included in the published studies and may not be suitable for this combination. OS results are still awaited. QoL was comparable to that with ET alone. (LoE/GoR : I/A) (90%) * For pre and peri with OS/OA, and post-menopausal women and men Notes for manuscript: a) Problems with QoL studies and methodology used b) General availability of new drugs very uneven around the world c) Discuss class effect of different CDKi and differences in toxicities which may influence treatment decision 24

25 ER POSITIVE / HER-2 NEGATIVE MBC The addition of a CDK4/6 inhibitor to Fulvestrant, in patients previously exposed to ET, provided significant improvement in median PFS (6 to 7 months) as well as improvement of QoL, and is one of the preferred treatment options, if a CDK4/6 inhibitor was not previously used. OS results are awaited. (LoE/GoR : I/A) (90%) * For pre and peri with OS/OA, and post-menopausal women and men Notes for manuscript: a) Discuss class effect of different CDKi and differences in toxicities which may influence treatment decision; b) this is an appropriate option in patients who progressed less than one year after adjuvant AI 25

26 ER POSITIVE / HER-2 NEGATIVE MBC The optimal sequence of endocrine-based therapy is uncertain. It depends on which agents were previously used (in the (neo)adjuvant or advanced settings), the burden of the disease, patients preference, costs and availability. Available options include AI, tamoxifen, fulvestrant, AI/fulvestrant + CDK4/6 inhibitor, AI/tamoxifen/fulvestrant + everolimus. In later lines also megestrol acetate and estradiol, as well as repetition of previously used agents, may be used. (LoE/GoR : I/A) (95%) It is currently unknown how the different combinations of endocrine + targeted agents compare with each other, and with single agent CT. Trials are ongoing. 26 * For pre and peri with OS/OA, and post-menopausal women and men

27 ER POSITIVE / HER-2 NEGATIVE MBC Everolimus and CDK4/6 inhibitors should NOT be used after disease progression on that specific agent (i.e. beyond progression). (LoE/GoR : NA/E) (74%) 27

28 ER POSITIVE / HER-2 NEGATIVE MBC At present, no validated predictive biomarker other than hormone receptor status exists to identify patients who will/will not benefit from the addition of a targeted agent (i.e. CDK4/6 inhibitor, mtor inhibitor) to endocrine therapy and none of the studied biomarkers is ready for use in clinical practice. Research efforts must continue. (LoE/GoR: I/E) (95%) 28

29 HER-2 POSITIVE ABC 29

30 ER + / HER-2+ MBC For the highly selected patients* with ER+/HER-2+ MBC, for whom ET + anti-her2 therapy was chosen as 1 st line therapy, dual anti- HER2 blockade (with either pertuzumab + trastuzumab or lapatinib + trastuzumab) can be used since it provides a benefit in PFS. This decision must be balanced against the higher side effects, higher costs and lack of OS benefit so far, as compared to ET + anti-her2 monotherapy. (LoE/GoR : I/B) (80%) * Defined in the manuscript 30

31 ER + / HER-2+ MBC For patients with ER+/HER-2+ MBC, for whom CT + anti-her2 therapy was chosen as 1 st line therapy and provided a benefit, it is reasonable to use ET + anti-her2 therapy as maintenance therapy, after stopping CT, although this strategy has not been studied in randomized trials. Duration of maintenance therapy should be until progression, unacceptable toxicity or patient request, and needs to be evaluated in clinical trials. (LoE/GoR: NA/B) (80%) There is no data to decide between single agent anti-her-2 or dual blockade, to combine with maintenance ET after stopping CT, in ER+/HER2+ ABC. Definition of MAINTENANCE THERAPY in ABC Guidelines: continuation of anti-her2 therapy and/or ET after discontinuation of CT Note in manuscript: in Cleopatra, maintenance was done with dual blockade alone (without ET) 31

32 TRIPLE NEGATIVE ABC 32

33 TRIPLE NEGATIVE AR+ ABC The androgen receptor (AR) is a potential target in TNBC. There are however no standardized methods to assay AR. Limited data suggest a low level of efficacy for AR antagonists agents such as bicalutamide and enzalutamide. At this time, these agents should not be used in routine clinical practice. (LoE/GoR: II/C) (85%) More definite trials are needed and research efforts must continue to optimize and standardize the determination of AR. 33

34 HEREDITARY ABC 34

35 HEREDITARY ABC GENETIC TESTING In the setting of ABC, results from genetic testing may have therapeutic implications and should therefore be considered as early as possible. (LoE/GoR: Expert Opinion/B) (100%) 35

36 HEREDITARY ABC GENETIC TESTING Genes to be tested for depend on personal and family history, however at present only germline mutations in BRCA1/2 have proven clinical utility and therapeutic impact. (LoE/GoR: I/A) (100%) Testing for other additional moderate- to high-penetrance genes may be considered, if deemed appropriate by the geneticist/genetic counsellor. However it must be clarified to the patient that at present, a mutation in another moderate-high penetrance gene has no direct clinical implications, for the patients themselves, in the setting of ABC. (LoE/GoR: Expert Opinion/C) (100%) 36

37 HEREDITARY ABC GENETIC TESTING New statement The therapeutic implications of somatic BRCA1/2 mutations in breast tumors need to be further explored within a research setting and should not be used for decision making in routine clinical practice. (LoE/GoR: NA/E) (83%) 37

38 HEREDITARY ABC PARPi New statement The PARP inhibitor olaparib is a reasonable treatment option for patients with BRCA-associated triple negative or luminal (after progression on endocrine therapy) ABC, previously treated with an anthracycline with/without a taxane (in the adjuvant and/or metastatic setting), since its use is associated with a PFS benefit, improvement in QoL and a favorable toxicity profile. OS results are awaited. It is unknown how PARP inhibitors compare with platinum compounds in this setting and their efficacy in truly platinum-resistant tumors. (LoE/GoR: I/B) (80%) 38

39 BIOSIMILARS 39

40 BIOSIMILARS New statement The ABC community strongly supports the use of biosimilars both for treatment of breast cancer (i.e. trastuzumab) and for supportive care (i.e. growth factors). To be used, the biosimilar must be approved after passing the stringent development and validation processes required by EMA or FDA or other similarly strict authority. (LoE/GoR: I/A) (90%) 40

41 PRECISION MEDICINE 41

42 PRECISION MEDICINE NOT RECOMMENDED for ROUTINE CLINICAL PRACTICE: Multigene panels Circulating tumour DNA (ctdna) assessment Immunotherapy 42

43 OTHER Management of Radio-necrosis after stereotactic radiotherapy for brain metastases Management of Chemotherapy-Induced Peripheral Neurotoxicity Management of Hand-and-Foot Syndrome Management of Mucositis 43

44 BRAIN METASTASES New statement Radio-necrosis after stereotactic radiotherapy for brain metastases is an uncommon complication that may occur specially with longer survival and follow-up, and in particular in cases of re-irradiation. Differential diagnosis with tumor progression is often difficult. Treatment of symptomatic patients with a course of high dose steroids is the first treatment of choice. If no response, bevacizumab may be used, as an option to decrease the surrounding edema, usually at a dose of 7.5 mg/kg every 2 weeks, for a median of four cycles. Prospective randomized trials are needed to validate further this option. (LoE/GoR: III/B) (61%) 44

45 ABC IMPORTANT DEFINITIONS 45

46 New statement ADEQUATE OVARION SUPPRESSION (OFS) IN THE CONTEXT OF ABC Adequate OFS for ABC premenopausal patients can be obtained through bilateral ovariectomy, continuous use of GnRH agonists or ovarian function ablation through pelvic radiotherapy (this latter is not always effective and therefore is the least preferred option). If a GnRH agonist is used in this age group, it should usually be given on a q4w basis to optimize OFS. (LoE/GoR: I/A) (85%) Efficacy of OFS must be initially confirmed analytically through serial evaluations of serum estradiol, even in the presence of amenorrhea, specially if an AI is administered. (LoE/GoR: Expert Opinion/B) As all endocrine interventions for premenopausal patients with endocrineresponsive ABC require indefinite OFS, choosing one method over the other requires balance of patient s wish for potentially preserving fertility, compliance with frequent injections over long period of time, and cost. Notes for manuscript: a) frequency and type of evaluations and for how long; b) GnRH 46 q3 months is not routinely recommended

47 MAINTENANCE THERAPY New statement In the context of ABC Guidelines, maintenance therapy refers to the continuation of anti-her2 therapy and/or endocrine therapy after discontinuation of chemotherapy. 47

48 INTEGRATIVE MEDICINE Complementary and Integrative Medicine (CIM) represents the use of complementary treatments side by side with conventional approaches in a proper therapeutic environment. (LoE: Expert opinion) Interventions with beneficial effects Interventions with detrimental effects 48

49 The ABC Global Alliance Continuing the work of the ABC Consensus Conference and Guidelines 54

50 ABC Global Alliance Who We Are: A multi-stakeholder platform for all those interested in collaborating in common projects relating to advanced breast cancer (ABC) around the world Continuation of the work developed through the ABC International Consensus Conference and Guidelines Launched during the World Cancer Congress in Paris on 3 November 2016 Our Vision/Mission: To improve and extend the lives of women and men living with ABC in all countries worldwide and to fight for a cure To raise awareness of advanced breast cancer and lobby worldwide for the improvement of the lives of ABC patients Website ABCGlobalAlliance@eso.net Social 50

51 ABC GLOBAL CHARTER 10 goals for the next 10 years 1. Double median overall survival for patients with ABC by Improve Quality of Life for patients with ABC in clinical practice 3. Improve availability of robust epidemiology and outcomes data for ABC 4. Increase availability and access to multidisciplinary care, including palliative, supportive, and psychosocial assistance for patients, families, and caregivers to ensure patients are receiving the best treatment experience 5. Strive for all patients with ABC to have financial support for treatment, care and assistance if unable to work 6. Offer communication skills training to all healthcare providers 7. Provide accurate and up-to-date ABC-specific information tools to all patients who want them 8. Increase public understanding of ABC 9. Improve access to non-clinical supportive services for ABC 10. Protect workforce rights for patients with ABC 51

52 Scientific Committee Coordinating Chair Fatima Cardoso Breast Unit, Champalimaud Clinical Center, Lisbon, PT Co-Chairs Elzbieta Senkus Dept. of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, PL Evi Papadopoulos Europa Donna, Nicosia, CY Chairs Eric P. Winer Breast Oncology Center, Dana-Farber Cancer Institute, Boston, US Larry Norton Breast Cancer Programs, Memorial Sloan-Kettering Cancer Centre, New York, US Alberto Costa European School of Oncology Milan, IT and Bellinzona, CH Scientific Committee Members Matti S. Aapro MO Clinique de Genolier, Institut Multidisciplinaire d Oncologie Genolier, CH Fabrice André Department of Medical Oncology, Gustae Roussy Institute, Villejuif, FR Nadia Harbeck Breast Centre, University of Munich, Munich, DE 52

53 All Faculty and panel members Bertha Aguilar Lopez, MX - Carlos H. Barrios, BR - Jonas Bergh, SE - Elizabeth Bergsten Nordström, SE Laura Biganzoli, IT - Christine B. Boers-Doets, NL - Anna Cabanes, US - Maria João Cardoso, PT - Lisa A. Carey, US - Dian CJ M. Corneliussen-James, US - Javier Cortés, ES - Giuseppe Curigliano, IT - Véronique Diéras, FR Matthew J. Ellis, US - Nagi S. El Saghir, LB - Alexandru Eniu, RO Lesley Fallowfield, UK - Prudence A. Francis, AU - Karen Gelmon, CA - Mary K. Gospodarowicz, CA - Renate Haidinger, DE - Stephen R.D. Johnston, UK Bella Kaufman, IL - Smruti Koppikar, IN - Ian E. Krop, US - Danni Manzi, UK - Norbert Marschner, DE - Musa Mayer, US - Shirley A. Mertz, US - Gertrude Nakigudde, UG - Birgitte V. Offersen, DK - Shinji Ohno, JP Olivia Pagani, CH - Shani Paluch-Shimon, IL - Frédérique Penault-Llorca, FR Aleix Prat, ES - Hope S. Rugo, US - Timo Schinköthe, DE - George W. Sledge, US Danielle Spence, AU - Christoph Thomssen, DE Nicholas C. Turner, UK - Daniel A. Vorobiof, ZA - Nikhil Wagle, US - Binghe Xu, CN 53

54 All Faculty and panel members Bertha Aguilar Lopez, MX - Carlos H. Barrios, BR - Jonas Bergh, SE - Elizabeth Bergsten Nordström, SE Laura Biganzoli, IT - Christine B. Boers-Doets, NL - Anna Cabanes, US - Maria João Cardoso, PT - Lisa A. Carey, US - Dian CJ M. Corneliussen-James, US - Javier Cortés, ES - Giuseppe Curigliano, IT - Véronique Diéras, FR Matthew J. Ellis, US - Nagi S. El Saghir, LB - Alexandru Eniu, RO Lesley Fallowfield, UK - Prudence A. Francis, AU - Karen Gelmon, CA - Mary K. Gospodarowicz, CA - Renate Haidinger, DE - Stephen R.D. Johnston, UK Bella Kaufman, IL - Smruti Koppikar, IN - Ian E. Krop, US - Danni Manzi, UK - Norbert Marschner, DE - Musa Mayer, US - Shirley A. Mertz, US - Gertrude Nakigudde, UG - Birgitte V. Offersen, DK - Shinji Ohno, JP Olivia Pagani, CH - Shani Paluch-Shimon, IL - Frédérique Penault-Llorca, FR Aleix Prat, ES - Hope S. Rugo, US - Timo Schinköthe, DE - George W. Sledge, US Danielle Spence, AU - Christoph Thomssen, DE Nicholas C. Turner, UK - Daniel A. Vorobiof, ZA - Nikhil Wagle, US - Binghe Xu, CN 54

55 In ABC Patient/Advocates are full and equal partners Evi Papadopoulos Europa Donna Musa Mayer AdvancedBC.org Dian "CJ" Corneliussen-James METAvivor Danielle Spence BCNA Gertrude Nakigudde Uganda Women s Cancer Support Organisation Anna Cabanes Susan G. Komen Shirley Mertz MBCN Renate Haidinger Brustkrebs Deutschland e.v. Maria Joao Cardoso Mama Help Danni Manzi Breast Cancer Care Bertha Aguilar Lopez ULACCAM 55

56 ESO S STAFF 56

57 57